Alnylam Pharmaceuticals | ALNY - Ebitda

Stock Price
318.85
Daily Change
-9.88 -3.01%
Monthly
0.06%
Yearly
21.62%
Q2 Forecast
309.25

Alnylam Pharmaceuticals reported $145.22M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD -24.17M 18.91M Dec/2025
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Novartis USD 5.84B 235M Sep/2025
PTC Therapeutics USD 20.63M 53.74M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Sanofi EUR 5.66B 3.77B Sep/2025
Sarepta Therapeutics USD -168.03M 294.45M Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xencor USD -51.05M 55.28M Dec/2025